O	0	10	Inhibition	Inhibition	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	23	autophagy	autophagy	NN	B-NP
O	24	35	potentiates	potentiate	VBZ	B-VP
O	36	39	the	the	DT	B-NP
B-Cancer	40	49	antitumor	antitumor	JJ	I-NP
O	50	56	effect	effect	NN	I-NP
O	57	59	of	of	IN	B-PP
O	60	63	the	the	DT	B-NP
O	64	75	multikinase	multikinase	JJ	I-NP
O	76	85	inhibitor	inhibitor	NN	I-NP
O	86	95	sorafenib	sorafenib	NN	I-NP
O	96	98	in	in	IN	B-PP
B-Cancer	99	113	hepatocellular	hepatocellular	JJ	B-NP
I-Cancer	114	123	carcinoma	carcinoma	NN	I-NP
O	123	124	.	.	.	O

O	126	137	Multikinase	Multikinase	NN	B-NP
O	138	147	inhibitor	inhibitor	NN	I-NP
O	148	157	sorafenib	sorafenib	NN	I-NP
O	158	166	inhibits	inhibit	VBZ	B-VP
O	167	180	proliferation	proliferation	NN	B-NP
O	181	184	and	and	CC	I-NP
O	185	197	angiogenesis	angiogenesis	NN	I-NP
O	198	200	of	of	IN	B-PP
B-Cancer	201	207	tumors	tumor	NNS	B-NP
O	208	210	by	by	IN	B-PP
O	211	222	suppressing	suppress	VBG	B-VP
O	223	226	the	the	DT	B-NP
O	227	230	Raf	Raf	NN	I-NP
O	230	231	/	/	SYM	B-NP
O	231	234	MEK	MEK	NN	I-NP
O	234	235	/	/	SYM	I-NP
O	235	238	ERK	ERK	NN	I-NP
O	239	248	signaling	signaling	NN	I-NP
O	249	256	pathway	pathway	NN	I-NP
O	257	260	and	and	CC	I-NP
O	261	265	VEGF	VEGF	NN	I-NP
O	266	274	receptor	receptor	NN	I-NP
O	275	283	tyrosine	tyrosine	NN	I-NP
O	284	290	kinase	kinase	NN	I-NP
O	290	291	.	.	.	O

O	292	294	It	It	PRP	B-NP
O	295	308	significantly	significantly	RB	B-ADVP
O	309	317	prolongs	prolong	VBZ	B-VP
O	318	324	median	median	JJ	B-NP
O	325	333	survival	survival	NN	I-NP
O	334	336	of	of	IN	B-PP
O	337	345	patients	patient	NNS	B-NP
O	346	350	with	with	IN	B-PP
O	351	359	advanced	advance	VBN	B-NP
B-Cancer	360	374	hepatocellular	hepatocellular	JJ	I-NP
I-Cancer	375	384	carcinoma	carcinoma	NN	I-NP
O	385	386	(	(	(	O
B-Cancer	386	389	HCC	HCC	NN	B-NP
O	389	390	)	)	)	O
O	391	394	but	but	CC	O
O	395	398	the	the	DT	B-NP
O	399	407	response	response	NN	I-NP
O	408	410	is	be	VBZ	B-VP
O	411	418	disease	disease	NN	B-NP
O	418	419	-	-	HYPH	O
O	419	430	stabilizing	stabilize	VBG	B-VP
O	431	434	and	and	CC	O
O	435	445	cytostatic	cytostatic	JJ	B-ADJP
O	446	452	rather	rather	RB	B-PP
O	453	457	than	than	IN	I-PP
O	458	461	one	one	CD	B-NP
O	462	464	of	of	IN	B-PP
B-Cancer	465	470	tumor	tumor	NN	B-NP
O	471	481	regression	regression	NN	I-NP
O	481	482	.	.	.	O

O	483	485	To	To	TO	B-VP
O	486	493	examine	examine	VB	I-VP
O	494	497	the	the	DT	B-NP
O	498	508	mechanisms	mechanism	NNS	I-NP
O	509	519	underlying	underlie	VBG	B-VP
O	520	523	the	the	DT	B-NP
O	524	532	relative	relative	JJ	I-NP
O	533	543	resistance	resistance	NN	I-NP
O	544	546	in	in	IN	B-PP
B-Cancer	547	550	HCC	HCC	NN	B-NP
O	550	551	,	,	,	O
O	552	554	we	we	PRP	B-NP
O	555	567	investigated	investigate	VBD	B-VP
O	568	571	the	the	DT	B-NP
O	572	576	role	role	NN	I-NP
O	577	579	of	of	IN	B-PP
O	580	589	autophagy	autophagy	NN	B-NP
O	589	590	,	,	,	O
O	591	593	an	an	DT	B-NP
O	594	608	evolutionarily	evolutionarily	RB	I-NP
O	609	618	conserved	conserve	VBN	I-NP
O	619	623	self	self	AFX	I-NP
O	623	624	-	-	HYPH	I-NP
O	624	633	digestion	digestion	NN	I-NP
O	634	641	pathway	pathway	NN	I-NP
O	641	642	,	,	,	O
O	643	645	in	in	IN	B-PP
B-Cell	646	654	hepatoma	hepatoma	NN	B-NP
I-Cell	655	660	cells	cell	NNS	I-NP
O	661	663	in	in	FW	B-ADVP
O	664	669	vitro	vitro	FW	I-ADVP
O	670	673	and	and	CC	O
O	674	676	in	in	FW	B-ADVP
O	677	681	vivo	vivo	FW	I-ADVP
O	681	682	.	.	.	O

O	683	692	Sorafenib	Sorafenib	NN	B-NP
O	693	702	treatment	treatment	NN	I-NP
O	703	706	led	lead	VBD	B-VP
O	707	709	to	to	TO	B-PP
O	710	722	accumulation	accumulation	NN	B-NP
O	723	725	of	of	IN	B-PP
B-Cellular_component	726	740	autophagosomes	autophagosome	NNS	B-NP
O	741	743	as	as	IN	B-SBAR
O	744	753	evidenced	evidence	VBN	B-VP
O	754	756	by	by	IN	B-PP
O	757	767	conversion	conversion	NN	B-NP
O	768	772	from	from	IN	B-PP
O	773	776	LC3	LC3	NN	B-NP
O	776	777	-	-	HYPH	I-NP
O	777	778	I	I	NN	I-NP
O	779	781	to	to	TO	B-PP
O	782	785	LC3	LC3	NN	B-NP
O	785	786	-	-	HYPH	O
O	786	788	II	II	CD	B-NP
O	789	797	observed	observe	VBN	B-VP
O	798	800	by	by	IN	B-PP
O	801	811	immunoblot	immunoblot	NN	B-NP
O	812	814	in	in	IN	B-PP
B-Cell	815	819	Huh7	Huh7	NN	B-NP
O	819	820	,	,	,	I-NP
B-Cell	821	824	HLF	HLF	NN	I-NP
O	825	828	and	and	CC	I-NP
B-Cell	829	832	PLC	PLC	NN	I-NP
I-Cell	832	833	/	/	SYM	B-NP
I-Cell	833	836	PRF	PRF	NN	I-NP
I-Cell	836	837	/	/	SYM	B-NP
I-Cell	837	838	5	5	CD	B-NP
I-Cell	839	844	cells	cell	NNS	I-NP
O	844	845	.	.	.	O

O	846	850	This	This	DT	B-NP
O	851	860	induction	induction	NN	I-NP
O	861	864	was	be	VBD	B-VP
O	865	868	due	due	IN	B-PP
O	869	871	to	to	TO	B-PP
O	872	882	activation	activation	NN	B-NP
O	883	885	of	of	IN	B-PP
O	886	896	autophagic	autophagic	JJ	B-NP
O	897	901	flux	flux	NN	I-NP
O	901	902	,	,	,	O
O	903	905	as	as	IN	B-SBAR
O	906	911	there	there	EX	B-NP
O	912	915	was	be	VBD	B-VP
O	916	923	further	further	JJ	B-NP
O	924	932	increase	increase	NN	I-NP
O	933	935	in	in	IN	B-PP
O	936	939	LC3	LC3	NN	B-NP
O	939	940	-	-	HYPH	O
O	940	942	II	II	CD	B-NP
O	943	953	expression	expression	NN	I-NP
O	954	958	upon	upon	IN	B-PP
O	959	968	treatment	treatment	NN	B-NP
O	969	973	with	with	IN	B-PP
O	974	983	lysosomal	lysosomal	JJ	B-NP
O	984	994	inhibitors	inhibitor	NNS	I-NP
O	994	995	,	,	,	O
O	996	1001	clear	clear	JJ	B-NP
O	1002	1009	decline	decline	NN	I-NP
O	1010	1012	of	of	IN	B-PP
O	1013	1016	the	the	DT	B-NP
O	1017	1026	autophagy	autophagy	NN	I-NP
O	1027	1036	substrate	substrate	NN	I-NP
O	1037	1040	p62	p62	NN	I-NP
O	1040	1041	,	,	,	O
O	1042	1045	and	and	CC	O
O	1046	1048	an	an	DT	B-NP
O	1049	1053	mRFP	mRFP	NN	I-NP
O	1053	1054	-	-	HYPH	B-NP
O	1054	1057	GFP	GFP	NN	I-NP
O	1057	1058	-	-	HYPH	I-NP
O	1058	1061	LC3	LC3	NN	I-NP
O	1062	1074	fluorescence	fluorescence	NN	I-NP
O	1075	1081	change	change	NN	I-NP
O	1082	1084	in	in	IN	B-PP
O	1085	1094	sorafenib	sorafenib	NN	B-NP
O	1094	1095	-	-	HYPH	B-NP
O	1095	1102	treated	treat	VBN	I-NP
B-Cell	1103	1111	hepatoma	hepatoma	NN	I-NP
I-Cell	1112	1117	cells	cell	NNS	I-NP
O	1117	1118	.	.	.	O

O	1119	1128	Sorafenib	Sorafenib	NN	B-NP
O	1129	1138	inhibited	inhibit	VBD	B-VP
O	1139	1142	the	the	DT	B-NP
O	1143	1152	mammalian	mammalian	JJ	I-NP
O	1153	1159	target	target	NN	I-NP
O	1160	1162	of	of	IN	B-PP
O	1163	1172	rapamycin	rapamycin	NN	B-NP
O	1173	1180	complex	complex	NN	I-NP
O	1181	1182	1	1	CD	I-NP
O	1183	1186	and	and	CC	O
O	1187	1190	its	its	PRP$	B-NP
O	1191	1201	inhibition	inhibition	NN	I-NP
O	1202	1205	led	lead	VBD	B-VP
O	1206	1208	to	to	TO	B-PP
O	1209	1221	accumulation	accumulation	NN	B-NP
O	1222	1224	of	of	IN	B-PP
O	1225	1228	LC3	LC3	NN	B-NP
O	1228	1229	-	-	HYPH	B-NP
O	1229	1231	II	II	CD	I-NP
O	1231	1232	.	.	.	O

O	1233	1248	Pharmacological	Pharmacological	JJ	B-NP
O	1249	1259	inhibition	inhibition	NN	I-NP
O	1260	1262	of	of	IN	B-PP
O	1263	1273	autophagic	autophagic	JJ	B-NP
O	1274	1278	flux	flux	NN	I-NP
O	1279	1281	by	by	IN	B-PP
O	1282	1293	chloroquine	chloroquine	NN	B-NP
O	1294	1303	increased	increase	VBD	B-VP
O	1304	1313	apoptosis	apoptosis	NN	B-NP
O	1314	1317	and	and	CC	O
O	1318	1327	decreased	decrease	VBD	B-VP
B-Cell	1328	1332	cell	cell	NN	B-NP
O	1333	1342	viability	viability	NN	I-NP
O	1343	1345	in	in	IN	B-PP
B-Cell	1346	1354	hepatoma	hepatoma	NN	B-NP
I-Cell	1355	1360	cells	cell	NNS	I-NP
O	1360	1361	.	.	.	O

O	1362	1367	siRNA	siRNA	NN	B-NP
O	1367	1368	-	-	HYPH	B-PP
O	1368	1376	mediated	mediate	VBN	B-NP
O	1377	1386	knockdown	knockdown	NN	I-NP
O	1387	1389	of	of	IN	B-PP
O	1390	1393	the	the	DT	B-NP
O	1394	1398	ATG7	ATG7	NN	I-NP
O	1399	1403	gene	gene	NN	I-NP
O	1404	1408	also	also	RB	B-ADVP
O	1409	1419	sensitized	sensitize	VBD	B-VP
B-Cell	1420	1428	hepatoma	hepatoma	NN	B-NP
I-Cell	1429	1434	cells	cell	NNS	I-NP
O	1435	1437	to	to	TO	B-VP
O	1438	1447	sorafenib	sorafenib	VB	I-VP
O	1447	1448	.	.	.	O

O	1449	1456	Finally	Finally	RB	B-ADVP
O	1456	1457	,	,	,	O
O	1458	1467	sorafenib	sorafenib	NN	B-NP
O	1468	1475	induced	induce	VBD	B-VP
O	1476	1485	autophagy	autophagy	NN	B-NP
O	1486	1488	in	in	IN	B-PP
B-Cancer	1489	1493	Huh7	Huh7	NN	B-NP
I-Cancer	1494	1503	xenograft	xenograft	NN	I-NP
I-Cancer	1504	1510	tumors	tumor	NNS	I-NP
O	1511	1513	in	in	IN	B-PP
O	1514	1518	nude	nude	JJ	B-NP
O	1519	1523	mice	mouse	NNS	I-NP
O	1524	1527	and	and	CC	O
O	1528	1544	coadministration	coadministration	NN	B-NP
O	1545	1549	with	with	IN	B-PP
O	1550	1561	chloroquine	chloroquine	NN	B-NP
O	1562	1575	significantly	significantly	RB	B-ADVP
O	1576	1586	suppressed	suppress	VBD	B-VP
B-Cancer	1587	1592	tumor	tumor	NN	B-NP
O	1593	1599	growth	growth	NN	I-NP
O	1600	1608	compared	compare	VBN	B-PP
O	1609	1613	with	with	IN	B-PP
O	1614	1623	sorafenib	sorafenib	NN	B-NP
O	1624	1629	alone	alone	RB	B-ADVP
O	1629	1630	.	.	.	O

O	1631	1633	In	In	IN	B-PP
O	1634	1644	conclusion	conclusion	NN	B-NP
O	1644	1645	,	,	,	O
O	1646	1655	sorafenib	sorafenib	NN	B-NP
O	1656	1670	administration	administration	NN	I-NP
O	1671	1678	induced	induce	VBD	B-VP
B-Cellular_component	1679	1692	autophagosome	autophagosome	NN	B-NP
O	1693	1702	formation	formation	NN	I-NP
O	1703	1706	and	and	CC	O
O	1707	1715	enhanced	enhance	VBD	B-VP
O	1716	1726	autophagic	autophagic	JJ	B-NP
O	1727	1735	activity	activity	NN	I-NP
O	1735	1736	,	,	,	O
O	1737	1742	which	which	WDT	B-NP
O	1743	1752	conferred	confer	VBD	B-VP
O	1753	1754	a	a	DT	B-NP
O	1755	1763	survival	survival	NN	I-NP
O	1764	1773	advantage	advantage	NN	I-NP
O	1774	1776	to	to	TO	B-PP
B-Cell	1777	1785	hepatoma	hepatoma	NN	B-NP
I-Cell	1786	1791	cells	cell	NNS	I-NP
O	1791	1792	.	.	.	O

O	1793	1804	Concomitant	Concomitant	JJ	B-NP
O	1805	1815	inhibition	inhibition	NN	I-NP
O	1816	1818	of	of	IN	B-PP
O	1819	1828	autophagy	autophagy	NN	B-NP
O	1829	1832	may	may	MD	B-VP
O	1833	1835	be	be	VB	I-VP
O	1836	1838	an	an	DT	B-NP
O	1839	1849	attractive	attractive	JJ	I-NP
O	1850	1858	strategy	strategy	NN	I-NP
O	1859	1862	for	for	IN	B-PP
O	1863	1872	unlocking	unlock	VBG	B-VP
O	1873	1876	the	the	DT	B-NP
B-Cancer	1877	1886	antitumor	antitumor	JJ	I-NP
O	1887	1896	potential	potential	NN	I-NP
O	1897	1899	of	of	IN	B-PP
O	1900	1909	sorafenib	sorafenib	NN	B-NP
O	1910	1912	in	in	IN	B-PP
B-Cancer	1913	1916	HCC	HCC	NN	B-NP
O	1916	1917	.	.	.	O

